尿毒清颗粒联合缬沙坦胶囊治疗糖尿病肾病大量蛋白尿临床观察

目的探讨糖尿病肾病大量蛋白尿采用尿毒清颗粒联合缬沙坦胶囊治疗的临床效果及安全性。方法回顾性分析137例肾病门诊及病房收治的糖尿病肾病患者,71例患者单纯给予缬沙坦胶囊口服,设为对照组,66例患者在对照组治疗基础上给予尿毒清颗粒温开水冲服,两组患者治疗4周后对比临床疗效、24 h尿微量蛋白、24 h尿蛋白定量、血肌酐(Cr)和尿素氮(BUN)水平,并观察两组患者在治疗过程中出现的不良反应。结果观察组临床总有效率[96.97%(64/66)]和对照组[74.65%(53/71)]比较明显较高,差异有统计学意义(P<0.05)。治疗后对照组和观察组24 h尿微量蛋白[(223.48±46.59)mg、(151.87±56.39)mg]、24 h尿蛋白定量[(2687.39±213.02)mg、(1582.64±138.76)mg]、Cr[(186.94±38.21)μmol/L、(137.73±29.28)μmol/L]及BUN水平[(10.77±2.06)mmol/L、(8.24±1.58)mmol/L]和治疗前对照组和观察组24 h尿微量蛋白[(431.25±73.86)mg,(428.29±72.53)mg],24 h尿蛋白定量[(4672.41±378.25)mg,(4643.17±286.34)mg],Cr[(241.69±58.73)μmol/L,(237.04±66.59)μmol/L],BUN水平[(16.88±2.29)mmol/L,(17.02±3.15)mmol/L]相比明显较低,观察组降低程度更为明显,差异有统计学意义(P<0.05);观察组降低程度更为明显,差异有统计学意义(P<0.05)。两组患者在治疗过程中均未出现严重不良反应,各项指标检查未见明显异常。结论:尿毒清颗粒联合缬沙坦胶囊治疗糖尿病肾病大量蛋白尿的临床效果确切,明显改善肾功能相关指标,不良反应轻。

Clinical Observation of Niaoduqing Granule Combined with Valsartan Capsules in Treatment of Diabetic Nephropathy

Objective To investigate the clinical effect and safety of Niaoduqing Granule combined with Valsartan Capsules in the treatment of diabetes mellitus with massive proteinuria.Methods A retrospective analysis of 137 cases of diabetic nephropathy patients in hospital’s outpatient and nephropathy ward was carried out.Seventy-one patients treated with oral administration of Valsartan Capsules were as the control group and sixty-six patients on the basis of the control group given Niaoduqing Granules were as the treatment group.After 4 weeks treatment,the clinical efficacy,24 h urine albumin,24 h urine protein quantitation,serum levels of creatinine(Cr)and urea nitrogen(BUN)of the two groups were compared,and the adverse reactions were observed.Results The clinical total effective rate(96.97%,64/66)in the observation group were significantly higher than the control group(74.65%,53/71),and the difference was statistically significant(P<0.05).After treatment,the control group and the observation group’s 24 h urine albumin[(223.48±46.59)mg,(151.87±56.39)mg],24 h urine protein quantitation[(2687.39±213.02)mg,(1582.64±138.76)mg],Cr[(186.94±38.21)μmol/L,(137.73±29.28)μmol/L]and BUN[(10.77±2.06)mmol/L,(8.24±1.58)mmol/L]were significantly lower than those before treatment{24 h urine micro-protein[(431.25±73.86)mg,(428.29±72.53)mg],24 h urine protein quantitation[(4672.41±378.25)mg,(4643.17±286.34)mg],Cr[(241.69±58.73)μmol/L,(237.04±66.59)μmol/L],BUN[(16.88±2.29)mmol/L,(17.02±3.15)mmol/L]}and the observation group’s decreased more significantly,and the difference was statistically significant(P<0.05).There was no serious adverse reaction in the two groups during treatment,and no obvious abnormalities were found in all the indexes.Conclusion The clinical effect of Niaoduqing Granule combined with Valsartan Capsules in the treatment of massive proteinuria in diabetic nephropathy is exact,and it can significantly improve renal function related indicators and has mild side effects.